BI 1015550 is an orally active inhibitor of PDE4B with an IC 50 value of 7.2 nM. BI 1015550 has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD) .

BI 1015550 inhibited Lipopolysaccharides-induced TNF-α release and Phytohemagglutinin P-induced IL-2 release in human PBMCs with IC50 values of 35 nM and 9 nM, respectively.[2
BI 1015550 inhibited the release of TNF-α in rat whole blood with an IC50 value of 91 nM.[2]

BI 1015550 (Example 2) (0, 0.3, 1.0 and 3.0 mg/kg ; oral ; single dose) at 1.0 mg/kg weakened intestinal transit in rats, but did not significantly affect body weight.[1]
BI 1015550 prevented inflammation in rat lung tissue with an ED50 value of 0.1 mg/kg.[1]
BI 1015550 (0.01, 0.1 and 1.0 mg/kg ; oral ; single dose) reduced Lipopolysaccharides-induced TNF-α release in mouse plasma in a dose-dependent manner.[2]
BI 1015550 (0.1, 0.3 and 1.0 mg/kg ; oral ; single dose) inhibited lipopolysaccharide-induced neutrophil entry into the bronchoalveolar lavage fluid of male Suncus Murinus and Wistar rats.[2]
BI 1015550 (2.5 mg/kg and 12.5 mg/kg ; oral ; twice a day for 6 days) was effective in ameliorating the damage caused by bleomycin in mice.[2]